Zum Inhalt springen
an artificial intelligence illustration on the wall

Must Read: The Integration of Artificial Intelligence into Clinical Practice

  • KI

A research article in Applied Biosciences provides a fundamental synopsis of current research pertaining to artificial intelligence (AI) within the domain of clinical practice. Artificial intelligence has revolutionized the field of medicine and healthcare by providing innovative solutions to complex problems. One of the most important benefits of AI in clinical practice is its ability to investigate extensive volumes of data with efficiency and precision. This has led to the development of various applications that have improved patient outcomes and reduced the workload of healthcare professionals. AI can support doctors in making more accurate diagnoses and developing personalized treatment plans. Successful examples of AI applications are outlined for a series of medical specialties like cardiology, surgery, gastroenterology, pneumology, nephrology, urology, dermatology, orthopedics, neurology, gynecology, ophthalmology, pediatrics, hematology, and critically ill patients, as well as diagnostic methods. Special reference is made… 

more »Must Read: The Integration of Artificial Intelligence into Clinical Practice

Fisher Z is back

Hautnah am Zeitgeist, an den wichtigen Themen des politischen Weltgeschehens, interessiert an den Geschichten seiner erdachten, aber realen Protagonisten – das ist das musikalische Triptychon, das Fischer-Z schon seit jeher ausmachen, und das auch wieder auf dem neuen Album „Triptych“ und im Frühjahr 2024 live auf der Bühne präsentiert wird. Die Band, im Vergleich zur Debüt-LP „Word Salad“ (1979) auf drei Positionen umbesetzt und mit einer Gitarre mehr auf der Bühne, begeistert in ihren Live-Auftritten nach wie vor. Fischer-Z ist mit Hits wie „Marliese“ oder „So Long“ eine der Ikonen des New Wave und des White Reggae – Fischer-Z steht hier ebenbürtig neben The Police und Madness.

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

CUPERTINO, Calif., March 28, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at the 2024 Schizophrenia International Research Society (SIRS) Annual Meeting, to be held April 3-7, 2024, in Florence, Italy. Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

CHAPEL HILL, N.C., March 28, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced full year 2023 financial results, and provided clinical development and business updates. Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Technavio has announced its latest market research report titled Global Atomic Spectroscopy Market 2023-2027

Technavio: Atomic spectroscopy market size to increase by USD 2.21 billion

The Atomic Spectroscopy Market by Application, Type, and Geography – Forecast and Analysis 2023-2027 report has been published by Technavio. The market is set to experience significant expansion, fueled by several factors including government-led initiatives, technological innovations, and rising applications across various industries. The market, projected to witness a robust Compound Annual Growth Rate (CAGR) of 7.02% between 2022 and 2027, is estimated to increase by a staggering USD 2,214.33 million during this period. One of the primary drivers fueling market growth is the proactive approach taken by governmental organizations worldwide towards environmental testing and ensuring product safety standards. Furthermore, the proliferation of research activities, clinical trials, and the escalating demand for portable spectroscopy systems are contributing significantly to market expansion. Additionally, the burgeoning utilization of atomic spectroscopic techniques in diagnosing ailments like Alzheimer’s disease and monitoring neural health is further propelling market growth. Technological… 

more »Technavio: Atomic spectroscopy market size to increase by USD 2.21 billion

Multi-Criteria Decision Analysis (MCDA) for decision making

Abstract: Countries fundamentally base macro and micro decision making in the field of health on economic considerations, the budgetary impact of technologies being a major criterion. Nevertheless, the value of the technology of interest and its dimensions are more complex if we seek to take decisions based on the value itself. The use of structured and explicit approaches that require the assessment of multiple criteria that reflect the dimensions of this value may significantly improve the quality of the decision making. Multi-criteria decision analysis (MCDA) is a complementary decision-making tool that is able to systematically incorporate dimensions or domains such as ethical, organisational, legal, environmental and social considerations, as well as costs and benefits of medical interventions, together with the distinct perspectives of the interested parties. The objective of this article is to propose the implementation of analysis of non-core… 

more »Multi-Criteria Decision Analysis (MCDA) for decision making

Abzyme könnten Long-COVID erklären

Forscher von UVA Health haben eine mögliche Erklärung für einige der verwirrendsten Geheimnisse von COVID-19 und Long-COVID entdeckt. Die überraschenden Ergebnisse könnten zu neuen Behandlungen für die schwierigen akuten Auswirkungen von COVID-19, Long-COVID und möglicherweise anderen Viren führen. Forscher unter der Leitung von Steven L. Zeichner, MD, PhD von UVA, fanden heraus, dass COVID-19 den Körper einiger Menschen dazu veranlassen kann, Antikörper zu produzieren, die wie Enzyme wirken, die der Körper auf natürliche Weise zur Regulierung wichtiger Funktionen – zum Beispiel des Blutdrucks – verwendet. Verwandte Enzyme regulieren auch andere wichtige Körperfunktionen wie Blutgerinnung und Entzündungen. Ärzte können diese „Abzyme“ möglicherweise gezielt bekämpfen, um ihre unerwünschten Wirkungen zu stoppen. Wenn Abzyme mit unerwünschten Aktivitäten auch für einige Merkmale von Long-COVID verantwortlich sind, könnten Ärzte die Abzyme gezielt einsetzen, um die schwierigen und manchmal mysteriösen Symptome von COVID-19 und Long-COVID an… 

more »Abzyme könnten Long-COVID erklären

Headlands Research with Pfizer to Improve Diversity in Clinical Trials

SAN FRANCISCO, Calif., March 28, 2024 /PRNewswire/ — Headlands Research, a leading multinational network of clinical trial sites, today announced a fifth site, Headlands Research Orlando, as part of its partnership with Pfizer to create multiple clinical trial sites in areas with highly diverse demographics. „As an organization, we have been committed to diversity in clinical trials since day one,“ said Kyle Burtnett, CEO of Headlands Research. „Our partnership with Pfizer has been a critical component in our continued goal of making clinical research accessible to all.“ Home